In a bid to address the high cost of medicines, Food and Drug Administration Commissioner Janet Woodcock wrote the U.S. Patent and Trademark Office to express concern about moves that companies use to extend their monopolies as well as suggestions for curtailing some of these practices.
The Sept. 10 letter was sent in response to an executive order issued last June by President Biden to lower prescription drug prices, notably by promoting more competition through greater access to generics and biosimilar medicines. The Biden administration has targeted the rising cost of medicines as a key initiative and various proposals are winding their way through Congress.
Create a display name to comment
This name will appear with your comment